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ceft Ventricular Systolic
ysfunction in Rheumatoid Disease
hatia et al. (1) report an increased prevalence of left ventricular
LV) systolic dysfunction among patients with rheumatoid disease
n comparison to the general population based on a visual estimate
f echocardiographic LV ejection fraction. The investigators
cknowledge that this observation may be due to significantly higher
revalences of hypertension, diabetes mellitus, and smoking
mong the rheumatoid-disease patients, but they do not provide
nalyses adjusting for these important confounders. Thus, al-
hough ischemic heart disease (and preclinical atherosclerosis)
ccur prematurely in patients with rheumatoid disease, the present
tudy does not distinguish between traditional cardiovascular
isease risk factors as opposed to rheumatoid disease-related
actors being primarily responsible for their observation. Preva-
ences of previous myocardial infarction are comparable in the
atients and general population, and previous myocardial infarc-
ion is strongly related to LV systolic dysfunction among patients
ith rheumatoid disease. Thus the higher prevalence of LV
ystolic dysfunction among patients with rheumatoid disease is
omewhat difficult to reconcile with these two observations.
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EFERENCE
. Bhatia GS, Sosin MD, Patel JV, et al. Left ventricular systolic
dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll
Cardiol 2006;47:1169–74.
EPLY
e thank Dr. Roman for her interest in our study (1). Reported
yocardial infarction (MI) was an independent predictor of left
entricular systolic dysfunction (LVSD) in both the rheumatoid
nd general populations, but the prevalence of LVSD was still
igher in the rheumatoid population despite the prevalence of
eported MI being not significantly different between the 2
opulations (1). This may still relate to ischemic heart disease
IHD), which is more prevalent among rheumatoid patients (2).
ndeed, IHD may be less clinically apparent among rheumatoid
atients, partly because of their limited exercise tolerance due to
rthritis and also misinterpretation of the cause of chest pain. For
xample, rheumatoid patients are more likely to experience unrec-
gnized MI than nonrheumatoid control subjects (3). Further-
ore, cardiac ischemia (identified by thallium scintigraphy) was
ore frequent (and more often clinically silent) in rheumatoid satients compared to counterparts with osteoarthritis (4). In our
ohort (1), ischemic heart disease was the likely underlying cause of
VSD in subjects who had denied prior cardiac disease or cardiac
ymptoms.
Although diagnosed hypertension was more prevalent in the
ohort with rheumatoid disease, this may partly reflect the fact that
heir blood pressures were probably measured more frequently than
he general population cohort, and thus they were more likely to
ave been detected. Given that we found definite LVSD in only
.0% of treated hypertensive subjects in another arm of the
CHOES (Echocardiographic Heart of England Screening) study
5), hypertension seems unlikely to explain most of the excess
revalence of LVSD in the rheumatoid population.
Finally, although the exact mechanism of the high prevalence of
VSD in subjects with rheumatoid disease is still uncertain, this
oes not detract from the main conclusion of our study (1), namely
hat clinicians should be aware of the association and consider
chocardiographic screening for those at risk.
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nprotected Left Main Disease:
tent or Surgery?
n a recent issue of the Journal, Price et al. (1) reported the clinical
nd angiographic follow-up of 50 consecutive patients undergoing
irolimus-eluting stent implantation for unprotected left main
oronary-artery (ULMCA) stenosis. This carefully performed
tudy (i.e., 98% of angiographic follow-up) shows a surprisingly
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October 17, 2006:1727–30igh rate of major adverse cardiac events (MACE) (10% in-
ospital, 44% at 1 year). The study, however, presented several
mportant limitations, as already outlined by the investigators
hemselves (1), and in the accompanying editorial (2). We would
ike to comment on several other important issues.
In recent years interventional cardiologists have been trying to
efine the best strategy for bifurcation coronary stenting
provisional-T, V-stenting, or simultaneous kissing stent [SKS],
rush, culotte). Contemporary published data suggest that in case
f a small diameter side branch (SB), stenting of the main vessel
ith simple balloon angioplasty of the SB with provisional stenting
“only if needed”) seems to be associated with the best overall
ong-term outcome (3). The crush technique seems to have a
umber of disadvantages in cases of true bifurcation lesions with
mall SB, because the resulting 3 metal layers in the SB-ostium
end to increase the risk of restenosis (ISR) (4). It is therefore
ossible that the excess of ISR of the left circumflex ostium
bserved in the Price et al. (1) series was mainly related to the
articular adopted stenting strategy.
In our view, this high target lesion revascularization (TLR) rate
hould be interpreted cautiously. The majority of other investiga-
ors recently reported similar series showing encouraging TLR and
ACE rates at 6 and 12 months, clearly contrasting with the
esults of the Price et al. study (5–8).
In addition, we would propose not to be overly concerned by the
levated 1-year MACE rate (TLR: 38%) reported by Price et al.
1), but to pay more attention to some pharmacological and
natomical aspects enumerated below:
. The importance of the clopidogrel loading dose in such a
delicate procedure (the same patient without the loading dose
experienced 3 of the 5 in-hospital MACE).
. The ULMCA stenting strategy should be tailored to the
specific coronary anatomy (SKS or V-stenting in case of ostial
involvement of both major vessels; provisional-T stenting if
one of the ostia remains disease free).
Finally, in our opinion, percutaneous coronary intervention for
LMCA disease is progressively becoming a worldwide standard
f care; therefore, interventional cardiologists should make an
ffort to generate strong evidence supporting safety and long-term
fficacy of this very promising technique, utilizing data generated
rom tailored stented ULMCA with carefully performed clinical
nd angiographic follow-up protocols (1,5–8).
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EPLY
e appreciate the comments by Dr. Bonvini et al. regarding our
tudy (1). Their concerns appropriately highlight the difficulty in
efining the best strategy for approaching stent implantation
ithin the distal bifurcation of the unprotected left main coronary
rtery (ULMCA). The investigators believe our “elevated” rate of
ajor adverse cardiac events (MACE) could be due to use of the
crush” technique. In our study, the majority of patients (68%)
ere treated with simultaneous kissing stents (SKS), whereas only
small minority of patients (16%) underwent “crush” stenting.
herefore, our higher than expected MACE rate (44% at 9
onths) cannot be explained by the use of the “crush” technique
lone. We believe our increased late revascularization rate, com-
ared to other series, was likely due to our unusually high (98%)
ate of angiographic follow-up and the presence of distal left main
isease (DLMD) in nearly all (94%) of our patients.
Interestingly, a very recent report describing late follow-up after
MCA intervention with drug-eluting stents (DES) documented
utcomes similar to our report. In that study (2), the cumulative
ncidence of MACE was 30% in patients with DLMD; in those at
igh surgical risk (similar to two-thirds of the patients in our
tudy), the risk of MACE was 40%. Importantly, stenting
echnique (bifurcation versus main branch only) had no impact on
utcomes. It is difficult, however, to draw conclusions about the
ppropriate stent technique from any of the published data about
ES for ULMCA because the choice of technique in these studies
s operator-driven, presumably in response to specific lesion
haracteristics (angulation of the distal bifurcation, diameter and
egree of stenosis within the left circumflex, etc.).
We do agree with Dr. Bonvini et al. that a meticulous technical
pproach to ULMCA stenting is essential. We continue to use
ES to treat many patients with ULMCA disease. We have now
hanged our technique (based on our reported experience) in the
ollowing manner: 1) we always preload patients with 300 to 600
g of clopidogrel; 2) we always complete the stent implantation
rocedure with a high-pressure postdilation using noncompliant
